Member of Lyonbiopole
Aging, neurodegenerative diseases, metabolic disorders like diabetes, and also some cancer treatments including immuno & chemotherapies generate Peripheral Neuropathies. PN generates Hearing loss, sensitivity disorders, burning sensations, pain,...
Million of persons worldwide suffer from Peripheral Neuropathies.
Currently there is no EMA or FDA approved treatment preventing immuno & chemo-induced peripheral neuropathies (CIPN) or aging PN or diabetes PN.
Saxol, managed by skilled staff, develops patented neuroprotective compounds. Carba1, our lead compound and the first in a new class of drugs, NAMPT activator, provides neuroprotective effects.
Application market: Neurology & Mental Health Disorders, Oncology, Others
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Small Molecules
Created on nov. 27th, 2024 - 5 employees
Address
Saxol 31 Rue Gustave Eiffel 38000 Grenoble
You must be logged in and a member of Lyonbiopôle to see the contacts.
